$ANGO News
Last published 5d ago
- 5d agoANGOAngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer of the ...
- 1w agoANGOAngioDynamics to Participate in Upcoming Investor ConferencesBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient
- 3w agoANGOAngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IREBusiness WireProspective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer; new Category I CPT code for open pancreatic IRE takes effect
- 4w agoANGOAngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver CancerBusiness WirePolicy Applies Medical Necessity Criteria Across Medicare Administrative Contractor (MAC) Jurisdictions for Eligible Prostate and Liver Cancer Patients AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative
- 1mo agoANGOAngioDynamics, Inc. First Quarter of Fiscal 2027 Earnings Conference Call - ANGIODYNAMICS INCEarnings Call TranscriptsGood morning, and welcome to the AngioDynamics Fiscal Year 2027 First Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As
- 1mo agoANGOAngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and ProfitabilityBusiness WireDelivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on
- 1mo agoANGOAngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive OfficerBusiness WireMedical Technology Executive Brings More than 20 years of Leadership Experience, Including Cardiovascular, Endovascular and Oncology Markets, with a Track Record of Accelerating Growth and Improving Profitability Jim
- 1mo agoANGOAngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism EvidenceBusiness WireInvestigator-Led Study Will Evaluate Imaging Biomarkers That May Help Predict Thrombectomy Success and Inform Long-Term PE Care AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring
- 1mo agoANGOAngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026Business WireAngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today
- 3mo agoANGOCG 46TH ANNUAL GROWTH CONFERENCE - ANGIODYNAMICS INCEarnings Call TranscriptsThanks, everyone, for joining. My name is John Young. I'm one of Canaccord's senior medtech analysts, and we're thrilled to host Angio Dynamics. With us today is CEO Jim Clemmer and CFO Steve Trowbridge. We saw a very st
- 3mo agoANGOCG 46TH ANNUAL GROWTH CONFERENCE - ANGIODYNAMICS INCEarnings Call TranscriptsThanks, everyone, for joining. My name is John Young. I'm one of Canaccord's senior medtech analysts, and we're thrilled to host Angio Dynamics. With us today is CEO Jim Clemmer and CFO Steve Trowbridge. We saw a very st
- 3mo agoANGOAngioDynamics to Participate in Upcoming Investor ConferencesBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient
- 4mo agoANGOAngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year ProfitabilityBusiness WireDelivered its seventh consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on
- 4mo agoANGOAngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026Business WireAngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today
- 4mo agoANGOAngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)Business WireProspective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused
- 5mo agoANGOAngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes EffectBusiness WirePalmetto GBA Medicare Coverage Effective July 5, 2026 Advances NanoKnife IRE Reimbursement Access in Prostate and Liver Cancer, Building on Category I CPT Codes Toward Broader National Payer Coverage AngioDynamics,
- 5mo agoANGOAngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 6mo agoANGOAngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate CancerBusiness WirePivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 months Results Presented at AUA 2026 AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood
- 7mo agoANGOAngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued ProfitabilityBusiness WireMed Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised full year FY 2026 guidance for net sales and Adjusted
- 7mo agoANGOAngioDynamics to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 7mo agoANGOAngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026Business WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 8mo agoANGOAngioDynamics to Present at the Leerink Partners Global Healthcare ConferenceBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 8mo agoANGOAngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation PlatformBusiness WireGrowing Clinical Evidence and Physician Adoption Broaden NanoKnife IRE Technology as Treatment Option for Major Solid Tumor Types AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology
- 9mo agoANGOAngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism CareBusiness WireThe ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring
- 9mo agoANGOAngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to AdvanceBusiness WirePhysician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring
- 10mo agoANGOAngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased ProfitabilityBusiness WireMed Tech segment delivers fifth consecutive quarter of double-digit growth Strong adjusted EBITDA; and positive cash flow Three regulatory milestones support Mechanical Thrombectomy portfolio: Modified AlphaVac
- 10mo agoANGOAngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026Business WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 10mo agoANGOAngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today
- 1y agoANGOAngioDynamics to Participate in the UBS Global Healthcare ConferenceBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today
- 1y agoANGOAngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions ListBusiness WireFunction-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors AngioDynamics, Inc. (NASDAQ:ANGO), a medical
- 1y agoANGOAngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued MomentumBusiness WireMed Tech segment delivers fourth consecutive quarter of over 20% revenue growth Reported Adjusted EBITDA of $2.2 million compared to ($0.2) million in the prior year Continues to expect to be cash flow positive
- 1y agoANGOAngioDynamics to Present at the Canaccord Genuity 45th Annual Growth ConferenceBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality
- 1y agoANGOAngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb IschemiaBusiness WireTrial Investigates Use of Auryon Atherectomy System in Cases with Challenging Below-the-Knee Blockages AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the
- 1y agoANGOAngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European UrologyBusiness WirePeer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative
- 1y agoANGOAngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable GrowthBusiness WireMed Tech franchise delivers third consecutive quarter of over 20% revenue growth Reported strong adjusted EBITDA in the fourth quarter resulting in positive adjusted EBITDA for full fiscal year 2025 Drove $16.2
- 1y agoANGOAngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025Business WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 1y agoANGOAngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary EmbolismBusiness WireMulti-center, multi-national study builds on existing U.S. PE Clearance and CE Mark to assess mechanical thrombectomy treatment and long-term functional outcomes in intermediate-risk PE patients across
- 1y agoANGOAngioDynamics Reports Fiscal Year 2025 Third Quarter Financial ResultsBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality
- 1y agoANGOAngioDynamics to Host Virtual Cardiovascular Investor EventBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality
- 1y agoANGOAngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor EventBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 1y agoANGOAngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual ConferenceBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality
- 1y agoANGOAngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb IschemiaBusiness WireTrial Evaluates Effectiveness of Innovative Auryon Atherectomy System in Complex Below-the-Knee Cases AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring
- 1y agoANGOAngioDynamics Announces Publication of APEX-AV Trial Results in JSCAIBusiness WirePeer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment. AngioDynamics, Inc.
- 1y agoANGOAngioDynamics Reports Fiscal Year 2025 Second Quarter Financial ResultsBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality
- 1y agoANGOAngioDynamics to Present at the J.P. Morgan Healthcare ConferenceBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality
- 1y agoANGOAngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ SystemBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality
- 1y agoANGOAngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor EventBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 1y agoANGOAngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue AblationBusiness WireAngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient
- 2y agoANGOAngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® SystemBusiness WireInvestigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention AngioDynamics, Inc. (NASDAQ:ANGO), a leading
- 2y agoANGOAngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and LiverBusiness WireNew Codes Expand Market Access to Treatment with the NanoKnife® System AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the